Low intensity focused ultrasound (LOFU) modulates unfolded protein response and sensitizes prostate cancer to 17AAG

Oncoscience

Volumn 1, Issue 6, 2014, Pages 434-445

  Saha, Subhrajit ^a   Bhanja, Payel ^a   Partanen, Ari ^b   Zhang, Wei ^a   Liu, Laibin ^a   Tomé, Wolfgang A ^a,c   Guha, Chandan ^a,c  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b PHILIPS HEALTHCARE   (United States)

^c MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

17AAG; ER stress; Focused Ultrasound; Prostate Cancer; UPR

Indexed keywords

EID: 84940053308     PISSN: None     EISSN: 23314737     Source Type: Journal    
DOI: 10.18632/oncoscience.48     Document Type: Article

References (46)

1. Murat FJ, Poissonnier L, Rabilloud M, Belot A, Bouvier R, Rouviere O, Chapelon JY and Gelet A. Mid-term results demonstrate salvage high-intensity focused ultrasound (HIFU) as an effective and acceptably morbid salvage treatment option for locally radiorecurrent prostate cancer. Eur Urol. 2009; 55(3): 640-647.
2. Chopra R, Colquhoun A, Burtnyk M, N'Djin W A, Kobelevskiy I, Boyes A, Siddiqui K, Foster H, Sugar L, Haider MA, Bronskill M and Klotz L. MR Imagingcontrolled Transurethral Ultrasound Therapy for Conformal Treatment of Prostate Tissue: Initial Feasibility in Humans. Radiology. 2012; 265(1): 303-313.
3. Fry WJ, WulffVJ, Tucker D and Fry FJ. Physical Factors Involved in Ultrasonically Induced Changes in Living Systems: I. Identification of Non-Temperature Effects. J Acoust Soc Am. 1950; 22(6): 867-876.
4. O'Brien WD, Jr. Ultrasound-biophysics mechanisms. Prog Biophys Mol Biol. 2007; 93(1-3): 212-255.
5. Bailey M, Khokhlova V, Sapozhnikov O, Kargl S and Crum L. Physical mechanisms of the therapeutic effect of ultrasound (a review). Acoustical Physics. 2003; 49(4): 369-388.
6. Ron D and Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol. 2007; 8(7): 519-529.
7. Back SH, Schroder M, Lee K, Zhang K and Kaufman RJ. ER stress signaling by regulated splicing: IRE1/HAC1/XBP1. Methods. 2005; 35(4): 395-416.
8. Ma Y and Hendershot LM. The role of the unfolded protein response in tumour development: friend or foe? Nat Rev Cancer. 2004; 4(12): 966-977.
9. Mann MJ and Hendershot LM. UPR activation alters chemosensitivity of tumor cells. Cancer Biol Ther. 2006; 5(7): 736-740.
10. Williams CR, Tabios R, Linehan WM and Neckers L. Intratumor injection of the Hsp90 inhibitor 17AAG decreases tumor growth and induces apoptosis in a prostate cancer xenograft model. J Urol. 2007; 178(4 Pt 1): 1528-1532.
11. Egorin MJ, Rosen DM, WolffJH, Callery PS, Musser SM and Eiseman JL. Metabolism of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) by murine and human hepatic preparations. Cancer Res. 1998; 58(11): 2385-2396.
12. Seip R, Chin CT, Hall CS, Raju BI, Ghanem A and Tiemann K. Targeted ultrasound-mediated delivery of nanoparticles: on the development of a new HIFU-based therapy and imaging device. IEEE Trans Biomed Eng. 2010; 57(1): 61-70.
13. Li W, Cai X, Kim C, Sun G, Zhang Y, Deng R, Yang M, Chen J, Achilefu S, Wang LV and Xia Y. Gold nanocages covered with thermally-responsive polymers for controlled release by high-intensity focused ultrasound. Nanoscale. 2011; 3(4): 1724-1730.
14. ter Haar G, Shaw A, Pye S, Ward B, Bottomley F, Nolan R and Coady AM. Guidance on reporting ultrasound exposure conditions for bio-effects studies. Ultrasound Med Biol. 2011; 37(2): 177-183.
15. Duck FA. (1990). Physical properties of tissue: a comprehensive reference book: Academic Press).
16. Partanen A, Tillander M, Yarmolenko PS, Wood BJ, Dreher MR and Kohler MO. Reduction of peak acoustic pressure and shaping of heated region by use of multifoci sonications in MR-guided high-intensity focused ultrasound mediated mild hyperthermia. Med Phys. 2013; 40(1): 013301.
17. Supko JG, Hickman RL, Grever MR and Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol. 1995; 36(4): 305-315.
18. Egorin MJ, Zuhowski EG, Rosen DM, Sentz DL, Covey JM and Eiseman JL. Plasma pharmacokinetics and tissue distribution of 17-(allylamino)-17-demethoxygeldanamycin (NSC 330507) in CD2F1 mice1. Cancer Chemother Pharmacol. 2001; 47(4): 291-302.
19. Shang J. Quantitative measurement of events in the mammalian unfolded protein response. Methods. 2005; 35(4): 390-394.
20. Anelli T, Alessio M, Mezghrani A, Simmen T, Talamo F, Bachi A and Sitia R. ERp44, a novel endoplasmic reticulum folding assistant of the thioredoxin family. EMBO J. 2002; 21(4): 835-844.
21. Jessop CE, Chakravarthi S, Garbi N, Hammerling GJ, Lovell S and Bulleid NJ. ERp57 is essential for efficient folding of glycoproteins sharing common structural domains. EMBO J. 2007; 26(1): 28-40.
22. White E. Deconvoluting the context-dependent role for autophagy in cancer. Nat Rev Cancer. 2012; 12(6): 401-410.
23. Kon M, Kiffin R, Koga H, Chapochnick J, Macian F, Varticovski L and Cuervo AM. Chaperone-mediated autophagy is required for tumor growth. Sci Transl Med. 2011; 3(109): 109ra117.
24. Collins AT, Berry PA, Hyde C, Stower MJ and Maitland NJ. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res. 2005; 65(23): 10946-10951.
25. Collins AT, Habib FK, Maitland NJ and Neal DE. Identification and isolation of human prostate epithelial stem cells based on alpha(2)beta(1)-integrin expression. J Cell Sci. 2001; 114(Pt 21): 3865-3872.
26. Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods. 2005; 35(4): 373-381.
27. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, Shokat KM, Lavail MM and Walter P. IRE1 signaling affects cell fate during the unfolded protein response. Science. 2007; 318(5852): 944-949.
28. Lin JH, Li H, Zhang Y, Ron D and Walter P. Divergent effects of PERK and IRE1 signaling on cell viability. PLoS One. 2009; 4(1): e4170.
29. Wood BJ, Ramkaransingh JR, Fojo T, Walther MM and Libutti SK. Percutaneous tumor ablation with radiofrequency. Cancer. 2002; 94(2): 443-451.
30. Yarmolenko PS, Zhao Y, Landon C, Spasojevic I, Yuan F, Needham D, Viglianti BL and Dewhirst MW. Comparative effects of thermosensitive doxorubicin-containing liposomes and hyperthermia in human and murine tumours. Int J Hyperthermia. 2010; 26(5): 485-498.
31. Hynynen K, Watmough DJ and Mallard JR. Design of ultrasonic transducers for local hyperthermia. Ultrasound Med Biol. 1981; 7(4): 397-402.
32. Ahmed HU, Zacharakis E, Dudderidge T, Armitage JN, Scott R, Calleary J, Illing R, Kirkham A, Freeman A, Ogden C, Allen C and Emberton M. High-intensity-focused ultrasound in the treatment of primary prostate cancer: the first UK series. Br J Cancer. 2009; 101(1): 19-26.
33. Cordeiro ER, Cathelineau X, ThuroffS, Marberger M, Crouzet S and de la Rosette JJ. High-intensity focused ultrasound (HIFU) for definitive treatment of prostate cancer. BJU Int. 2012; 110(9): 1228-1242.
34. Illing RO, Kennedy JE, Wu F, ter Haar GR, Protheroe AS, Friend PJ, Gleeson FV, Cranston DW, Phillips RR and Middleton MR. The safety and feasibility of extracorporeal high-intensity focused ultrasound (HIFU) for the treatment of liver and kidney tumours in a Western population. Br J Cancer. 2005; 93(8): 890-895.
35. Kennedy JE. High-intensity focused ultrasound in the treatment of solid tumours. Nat Rev Cancer. 2005; 5(4): 321-327.
36. Zacharakis E, Ahmed HU, Ishaq A, Scott R, Illing R, Freeman A, Allen C and Emberton M. The feasibility and safety of high-intensity focused ultrasound as salvage therapy for recurrent prostate cancer following external beam radiotherapy. BJU Int. 2008; 102(7): 786-792.
37. Hanks GE, Hanlon AL, Schultheiss TE, Freedman GM, Hunt M, Pinover WH and Movsas B. Conformal external beam treatment of prostate cancer. Urology. 1997; 50(1): 87-92.
38. Kupelian P, Katcher J, Levin H, Zippe C, Suh J, Macklis R and Klein E. External beam radiotherapy versus radical prostatectomy for clinical stage T1-2 prostate cancer: therapeutic implications of stratification by pretreatment PSA levels and biopsy Gleason scores. Cancer J Sci Am. 1997; 3(2): 78-87.
39. Chan DA and Giaccia AJ. Harnessing synthetic lethal interactions in anticancer drug discovery. Nat Rev Drug Discov. 2011; 10(5): 351-364.
40. Yun J, Tomida A, Andoh T and Tsuruo T. Interaction between glucose-regulated destruction domain of DNA topoisomerase IIalpha and MPN domain of Jab1/CSN5. J Biol Chem. 2004; 279(30): 31296-31303.
41. Chatterjee S, Hirota H, BelfiCA, Berger SJ and Berger NA. Hypersensitivity to DNA cross-linking agents associated with up-regulation of glucose-regulated stress protein GRP78. Cancer Res. 1997; 57(22): 5112-5116.
42. Thorburn A and Debnath J. Targeting chaperonemediated autophagy in cancer. Sci Transl Med. 2011; 3(109): 109ps145.
43. Fillmore CM and Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res. 2008; 10(2): R25.
44. Phillips TM, McBride WH and Pajonk F. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. J Natl Cancer Inst. 2006; 98(24): 1777-1785.
45. Woodward WA, Chen MS, Behbod F, Alfaro MP, Buchholz TA and Rosen JM. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A. 2007; 104(2): 618-623.
46. Lagadec C, Vlashi E, Della Donna L, Dekmezian C and Pajonk F. Radiation-induced reprogramming of breast cancer cells. Stem Cells. 2012; 30(5): 833-844.